Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deaths In Esperion's Long-Term Bempedoic Acid Trial Spur Fears Of Commercial Delay

May 03 2018

• By Emily Hayes

Related Content

AstraZeneca’s <em>Farxiga</em> Label Includes, But Downplays, Bladder Cancer Risk

Jan 13 2014

Esperion Says FDA On Board With Filing Strategy For Bempedoic Acid

Mar 20 2017

PCSK9 Add-On Study Helps Esperion Cover All The Bases With Bempedoic Acid

Mar 27 2018

Esperion's Oral Bempedoic Acid Passes First Phase III Cholesterol Test

Mar 08 2018

Esperion Expects Speedy Regulatory Path For Bempedoic Acid/Zetia Combo

Jun 28 2017

Related Companies

Esperion Therapeutics, Inc.

Merck & Co., Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

AstraZeneca PLC

Express Scripts Holding Company

Additional Topics

Clinical Trials Drug Safety Research & Development Cardiovascular BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window